 Connection
Robert Belknap to Antitubercular Agents
This is a "connection" page, showing publications Robert Belknap has written about Antitubercular Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.582 |
|
|
|
-
Belknap RW. Current Medical Management of Pulmonary Tuberculosis. Thorac Surg Clin. 2019 Feb; 29(1):27-35.
Score: 0.578
-
Haas MK, Belknap RW. Updates in the Treatment of Active and Latent Tuberculosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):297-309.
Score: 0.558
-
Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018 10; 23(10):893-900.
Score: 0.553
-
Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic. Pediatr Infect Dis J. 2018 03; 37(3):224-228.
Score: 0.542
-
Belknap R, Holland D, Feng PJ, Millet JP, Cayl? JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Mir? JM, Villarino ME, Weiner M, Borisov AS. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 11 21; 167(10):689-697.
Score: 0.531
-
Flood J, Scott J, Belknap R. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 09 17; 373(12):1179.
Score: 0.457
-
Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, Reves R. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013; 8(1):e53373.
Score: 0.380
-
Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173.
Score: 0.193
-
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875.
Score: 0.176
-
Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467.
Score: 0.175
-
Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 08 22; 71(5):1320-1323.
Score: 0.161
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097.
Score: 0.049
-
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
Score: 0.048
-
Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0170521.
Score: 0.043
-
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65.
Score: 0.040
-
Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 07 15; 202(2):305-306.
Score: 0.040
-
Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 05; 15(5):570-580.
Score: 0.034
-
Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED. Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology. 2012 Jul; 17(5):772-91.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|